Enhanced Inhibition of Dipeptide Repeat Proteins

This invention relates to novel methods and systems for treating neurodegenerative diseases associated with dipeptide repeat proteins, focusing on enhancing the efficacy and delivery of Type I PRMT inhibitors.

The original patent disclosed the use of Type I PRMT inhibitors to decrease cellular toxicity caused by dipeptide repeat proteins. However, the existing approach has limitations, including suboptimal efficacy, inadequate delivery across the blood-brain barrier, and lack of combination therapies. The new inventive concept addresses these limitations by introducing secondary agents, gene therapies, and nanoparticle carriers to improve the treatment of neurodegenerative diseases.

The new claims introduce a system comprising a Type I PRMT inhibitor and a secondary agent that enhances the inhibitor's efficacy, such as antioxidants, anti-inflammatory agents, or neuroprotective compounds. Another embodiment involves administering a Type I PRMT inhibitor in combination with a gene therapy that reduces the expression of the C9ORF72 gene, thereby reducing the formation of toxic dipeptide repeat proteins. Additionally, the invention includes a composition of matter featuring a Type I PRMT inhibitor and a nanoparticle carrier that facilitates the inhibitor's delivery across the blood-brain barrier. The inventive concept also encompasses methods for diagnosing and monitoring neurodegenerative diseases associated with dipeptide repeat proteins.

The new claims introduce novel combinations of Type I PRMT inhibitors with secondary agents, gene therapies, and nanoparticle carriers, which provide a significant enhancement in efficacy and delivery compared to the original patent. The inventive concept's novelty lies in the synergistic effects achieved by these combinations, which overcome the limitations of the existing approach.

Alternative embodiments of the inventive concept could include the use of different types of secondary agents, gene therapies, or nanoparticle carriers. Additionally, the inventive concept could be adapted for treating other neurodegenerative diseases or disorders associated with dipeptide repeat proteins.

The enhanced inhibition of dipeptide repeat proteins has significant commercial potential in the treatment of neurodegenerative diseases, such as ALS and FTD. The target market includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel therapeutics for these diseases.